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Abstract
Background: West Nile virus (WNV) infection is asymptomatic in most individuals, with a minority developing symptoms
ranging from WNV fever to serious neuroinvasive disease. This study investigated the impact of host HLA on the outcome of
WNV disease.
Methods: A cohort of 210 non-Hispanic mostly white WNV
+ subjects from Canada and the U.S. were typed for HLA-A, B, C,
DP, DQ, and DR. The study subjects were divided into three WNV infection outcome groups: asymptomatic (AS),
symptomatic (S), and neuroinvasive disease (ND). Allele frequency distribution was compared pair-wise between the AS, S,
and ND groups using x2 and Fisher’s exact tests and P values were corrected for multiple comparisons (Pc). Allele
frequencies were compared between the groups and the North American population (NA) used as a control group. Logistic
regression analysis was used to evaluate the potential synergistic effect of age and HLA allele phenotype on disease
outcome.
Results: The alleles HLA-A*68, C*08 and DQB*05 were more frequently associated with severe outcomes (ND vs. AS,
PA*68=0.013/Pc=0.26, PC*08=0.0075/Pc=0.064, and PDQB1*05=0.029/Pc=0.68), However the apparent DQB1*05 association
was driven by age. The alleles HLA-B*40 and C*03 were more frequently associated with asymptomatic outcome (AS vs. S,
PB*40=0.021/Pc=0.58 and AS vs. ND PC*03=0.039/Pc=0.64) and their frequencies were lower within WNV
+ subjects with
neuroinvasive disease than within the North American population (NA vs.S ,PB*40=0.029 and NA vs. ND, PC*03=0.032).
Conclusions: Host HLA may be associated with the outcome of WNV disease; HLA-A*68 and C*08 might function as
‘‘susceptible’’ alleles, whereas HLA-B*40 and C*03 might function as ‘‘protective’’ alleles.
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Introduction
West Nile virus (WNV) infection is asymptomatic in most
individuals, with a minority developing symptoms ranging from
WNV fever (20% of cases) to more severe neuroinvasive disease
such as encephalitis, meningitis, meningoencephalitis, and acute
flaccid paralysis (,1% of cases) [1]. For the past 10 years WNV
has been recognized as the leading cause of arboviral encephalitis
in the U.S. WNV has claimed 1,176 lives in the U.S. and has been
responsible for 12,489 neuroinvasive disease cases reported to the
CDC between 1999 and 2010 [2]. Currently, no specific treatment
for WNV is available [3].
The host-virus dynamics underlying the development of severe
neurological symptoms in WNV is an area of active research.
Parallel studies in animals and humans have shown that both the
innateandadaptiveimmunesystems areinvolvedincontrolling and
clearing the virus [4]. However, circulating inflammatory factors
may facilitate the penetration of the virus into the central nervous
system [5], and the local inflammatory response required for viral
clearance has been linked to neuron loss and clinical outcome [6]. A
protective role for regulatory CD4
+ T cells (Tregs) has been
suggested based on higher levels of Tregs in asymptomatic subjects
than in symptomatic subjects and increased lethality of WNV
infection in mice depleted of Tregs [7]. Consistently, the symptoms
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22948of WNV infections tend to be more severe in immunocompromised
individuals, suggesting the involvement of the immune system in
infection control [8]. Additionally, elderly and WNV
+ subjects with
underlying conditions, such as hypertension and diabetes, may have
a higher risk of developing neuroinvasive disease compared to other
WNV
+ individuals [9]. Genetic mutations in the CCR5 receptor
[10] and in the OAS1 gene have also been associated with the
development of severe neuroinvasive disease [11,12].
In the present study genetic polymorphisms in the major
histocompatibility complex (MHC) on chromosome 6 were
compared in asymptomatic and symptomatic WNV
+ subjects
[13]. Region I of the MHC codes for HLA class I molecules,
including HLA-A, HLA-B, and HLA-C, whereas region II of the
MHC codes for HLA class II molecules, including HLA-DP,
HLA-DQ, and HLA-DR [13]. These proteins are key determi-
nates of the adaptive immune response through their involvement
in antigen presentation. In nucleated cells HLA class I molecules
present intracellular antigens to CD8
+ T cells, whereas in
professional antigen-presenting cells HLA class II proteins present
extracellular antigens to CD4
+ T cells [13]. The host adaptive
immune response depends on the ability of antigen-presenting cells
to present pathogen-derived peptides to CD4
+ and CD8
+ T cells.
The genes coding for class I and class II HLA molecules are
highly polymorphic [14]; this variability translates into minor
amino acid changes within the key domains of HLA-peptide
binding sites [15] and affects the ability of HLA proteins to present
specific pathogen-derived peptides [16,17,18]. Therefore, the
great variability of HLA molecules might translate into differential
abilities to present pathogen-derived peptides and to trigger
immune responses against invaders [19]. Many studies have
reported associations between HLA and the outcomes of infectious
diseases [20,21,22,23,24,25], including flavivirus diseases
[26,27,28,29,30,31,32,33]. However, no publication has yet
assessed associations between HLA and WNV infection outcome.
A comparison of the HLA alleles carried by asymptomatic,
symptomatic, and neuroinvasive disease groups of WNV
+ subjects
was undertaken to investigate the association between HLA
polymorphisms and WNV infection outcome. Weak or ‘‘suscep-
tible’’ HLA alleles are expected to occur more frequently in
subjects experiencing neuroinvasive disease than in asymptomatic
subjects. By contrast, ‘‘protective’’ HLA alleles are expected to
occur more frequently in asymptomatic subjects.
Results
Comparison of HLA allele phenotypes between groups of
WNV-infected individuals with different infection
outcomes
We compared the HLA allele phenotypes among three groups
of WNV-infected subjects, asymptomatic (AS), symptomatic (S),
and having neuroinvasive disease (ND) (Table 1) to examine the
correlation between HLA allele phenotype and WNV infection
outcome. Only 53 allele phenotypes with a frequency higher than
5% in our study population were included in this analysis (Table 2
and 3).
Before correction for multiple comparisons, five HLA allele
phenotypes were found to be associated with WNV infection
outcome. Three alleles were associated with a more severe
outcome; HLA-A*68 was found at a higher frequency in WNV
+
subjects with neuroinvasive disease than in asymptomatic subjects,
and it was found at an intermediate frequency in symptomatic
subjects (AS,S,ND, ORAS vs. ND=10.9, 95% CI 1.26–94.7;
P=0.013, Pc=0.26) (Table 2). While a lack of HLA-C*08
+ AS
subjects precluded calculation of an OR, a similar pattern was
observed for HLA-C*08 (AS,S,ND, PAS vs. ND=0.0075,
Pc=0.064) (Table 2), as well as for HLA-DQB1*05 (AS,S,ND,
ORAS vs. ND=2.5, 95% CI 1.09–6.09; P=0.029, Pc=0.68)
(Table 3). For this analysis, these three alleles are considered as
potential ‘‘susceptible’’ alleles.
Despite a significant difference of DQB1*02 allele phenotype
frequencies between AS and S subjects (AS,S, PAS vs. S=0.046,
Pc=0.85), DQB1*02 allele was not considered as associated with
WNV infection outcome as ND subjects did not possess a higher
frequency of DQB1*02 than S subjects (AS,S.ND).
Two alleles were associated with less severe WNV infection
outcome. HLA-B*40 was found at a higher frequency in
asymptomatic WNV
+ subjects than in symptomatic or neuroinva-
sive disease WNV
+ subjects (AS.S.ND, ORAS vs. S=0.3, 95%
Table 1. Demographics of the BSRI and McMaster cohorts.
BSRI cohort McMaster cohort Total
AS BSRI S (n=95) ND McMaster
(n=69) S BSRI S McMaster (n=46) (n=210)
Variable Group (n=33) (n=62)
n % n% n% n% n%
Ethnicity Don’t Know 1 1.4 0 0 0 0 0 0 1 0.5
Non-Hispanic 68 98.6 32 97 62 100 46 100 208 99
Not Reported 0 0 1 3 0 0 0 0 1 0.5
Gender Female 26 37.7 15 45.5 32 51.6 21 45.7 94 44.8
Male 43 62.3 18 54.5 30 48.4 25 54.3 116 55.2
Race Asian 0 0 0 0 0 0 2 4.3 2 1
B l a c k 1 1 . 4 0 00 00 01 0 . 5
Other 0 0 0 0 1 1.6 0 0 1 0.5
White 68 98.6 33 100 61 98.4 44 95.7 206 98.1
Age Mean 6 STDEV 49.8614.3 48.4611.0 48.7612.5 54.4615.3 50.3613.6
doi:10.1371/journal.pone.0022948.t001
HLA Association with WNV Infection Outcome
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was observed for HLA-C*03 (AS.S.ND, ORAS vs. ND=0.24,
95%CI 0.06–0.91; P=0.039, Pc=0.64,) (Table 2). For this
analysis, these alleles are considered as potential ‘‘protective’’
alleles.
Notably, in the white population alleles B*40:01 and C*03:04
are in linkage disequilibrium [34], and in our study a haplotype
analysis revealed that all B*40:01 except one were on the same
haplotype as C*03:04. However, not all C*03:04 alleles were on
the same haplotype as B*40:01, indicating that the effect of C*03
could be independent of B*40.
There was a higher frequency of subjects with one or more of
the potentially ‘‘susceptible’’ alleles A*68, C*08, or DQB1*05 (S
+)
in the neuroinvasive disease WNV
+ population than in the
Table 2. Pair-wise analysis of HLA Class I phenotype frequencies* in asymptomatic (AS), symptomatic (S), and neuroinvasive
disease (ND) groups of WNV
+ subjects.
Allele WNV+ AS S ND AS vs S AS vs ND Sv sN D
n
! and % X
2 P values (P) or Fisher’s P values (F)
HLA-A n=192 n=63 n=89 n=40
A*01 70 36.5 24 38.1 30 33.7 16 40.0 P=0.58 P=0.85 P=0.49
A*02 90 46.9 31 49.2 43 48.3 16 40.0 P=0.91 P=0.36 P=0.38
A*03 47 24.5 18 28.6 20 22.5 9 22.5 P=0.39 P=0.49 P=1.0
A*11 28 14.6 8 12.7 12 13.5 8 20.0 P=0.89 P=0.32 P=0.34
A*24 19 9.9 4 6.4 12 13.5 3 7.5 F=0.19 F=1.0 F=0.39
A*25 10 5.2 3 4.8 5 5.6 2 5.0 F=1.0 F=1.0 F=1.0
A*29 10 5.2 4 6.4 3 3.4 3 7.5 F=0.45 F=1.0 F=0.37
A*30 16 8.3 5 7.9 10 11.2 1 2.5 F=0.59 F=0.40 F=0.17
A*31 10 5.2 5 7.9 3 3.4 2 5.0 F=0.28 F=0.70 F=0.65
A*32 12 6.3 6 9.5 3 3.4 3 7.5 F=0.16 F=1.0 F=0.37
A*68 15 7.8 1 1.6 8 9.0 6 15.0 F=0.081 F=0.013/Pc=0.26 P=0.31
HLA-B n=191 n=63 n=89 n=39
B*07 45 23.6 14 22.2 22 24.7 9 23.1 P=0.72 P=0.92 P=0.84
B*08 51 26.7 15 23.8 24 27.0 12 30.8 P=0.66 P=0.44 P=0.66
B*13 11 5.8 5 7.9 5 5.6 1 2.6 F=0.74 F=0.40 F=0.67
B*14 10 5.2 1 1.6 5 5.6 4 10.3 F=0.40 F=0.069 F=0.45
B*15 22 11.5 6 9.5 13 14.6 3 7.7 P=0.35 F=1.0 F=0.39
B*18 18 9.4 4 6.4 11 12.4 3 7.7 F=0.28 F=1.0 F=0.55
B*27 10 5.2 3 4.8 5 5.6 2 5.1 F=1.0 F=1.0 F=1.0
B*35 35 18.3 13 20.6 13 14.6 9 23.1 P=0.33 P=0.77 P=0.24
B*40 20 10.5 12 19.1 6 6.7 2 5.1 P=0.021/Pc=0.58 F=0.073 F=1.0
B*44 46 24.1 12 19.1 21 23.6 13 33.3 P=0.50 P=0.10 P=0.25
B*51 15 7.9 7 11.1 6 6.7 2 5.1 P=0.34 F=0.48 F=1.0
B*55 12 6.3 5 7.9 7 7.9 0 0.0 F=1.0 F=0.15 F=0.10
B*57 16 8.4 7 11.1 4 4.5 5 12.8 F=0.20 F=1.0 F=0.13
HLA-C n=177 n=66 n=82 n=29
C*01 16 9.0 6 9.1 8 9.8 2 6.9 P=0.89 F=1.0 F=1.0
C*02 9 5.1 3 4.6 4 4.9 2 6.9 F=1.0 F=0.64 F=0.65
C*03 47 26.6 21 31.8 23 28.1 3 10.3 P=0.62 F=0.039/Pc=0.64 F=0.073
C*04 36 20.3 13 19.7 14 17.1 9 31.0 P=0.68 P=0.23 P=0.11
C*05 36 20.3 12 18.2 15 18.3 9 31.0 P=0.99 P=0.16 P=0.15
C*06 27 15.3 12 18.2 11 13.4 4 13.8 P=0.43 F=0.77 F=1.0
C*07 99 55.9 39 59.1 44 53.7 16 55.2 P=0.51 P=0.72 P=0.89
C*08 9 5.1 0 0.0 5 6.1 4 13.8 F=0.066 F=0.008/Pc=0.064 F=0.24
C*12 18 10.2 6 9.1 9 11.0 3 10.3 P=0.71 F=1.0 F=1.0
C*15 9 5.1 4 6.1 5 6.1 0 0.0 F=1.0 F=0.31 F=0.32
C*16 10 5.7 3 4.6 5 6.1 2 6.9 F=0.73 F=0.64 F=1.0
*Phenotype frequencies .5% are listed.
!n represents the number of subjects with a specific allele phenotype. Alleles in bold showed an uncorrected P,0.05 followed by a corrected Pc (P/Pc).
doi:10.1371/journal.pone.0022948.t002
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+ population; an intermediate frequency was
observed in the symptomatic WNV
+ population (AS=24%,
S=35%, ND=44%, PAS vs. ND=0.027; Figure 1, S
+). This trend
was strengthened when at least one ‘‘susceptible’’ allele and none
of the potentially ‘‘protective’’ alleles were present (S
+P
2,
AS=22%, S=28%, ND=46%, PAS vs. ND=0.009) (Figure 1).
Conversely, there was a higher frequency of subjects with at
least one of the potentially ‘‘protective’’ allele B*40 or C*03 (P
+)i n
the asymptomatic WNV
+ population than in the neuroinvasive
disease WNV
+ population; an intermediate frequency was
observed in the symptomatic WNV
+ population (AS=33%,
S=25%, ND=7%, PAS vs. ND=0.002 and PS vs. ND=0.029)
(Figure 1). The same trend was observed when at least one
‘‘protective’’ allele and no ‘‘susceptible’’ alleles were present;
however, the absence of ‘‘susceptible’’ alleles did not seem to
improve infection outcome (S
2P
+, AS=30%, S=19%, ND=7%,
PAS vs. ND=0.007) (Figure 1).
As expected, there was no difference between asymptomatic,
symptomatic and neuroinvasive disease WNV
+ subjects who did
not carry any of the ‘‘susceptible’’ or ‘‘protective’’ alleles (S
2P
2)
(Figure 1). In subjects carrying any ‘‘susceptible’’ allele in
combination with any ‘‘protective’’ allele (S
+P
+), no neuroinvasive
disease case was observed.
In this study, HLA genotyping data from two cohorts of WNV
+
subjects were analyzed. Previous studies characterized a high level
of diversity in the frequencies of HLA-A, B, and C alleles and
contrasting distribution patterns in different race or ethnic groups
[34] and our study only focused on non-Hispanic white individuals
Table 3. Pair-wise analysis of HLA Class II phenotype frequencies* in asymptomatic (AS), symptomatic (S), and neuroinvasive
disease (ND) groups of WNV
+ subjects.
Allele WNV+ AS S ND AS vs S AS vs ND Sv sN D
n
! and % X
2 P values (P) or Fisher’s P values (F)
HLA-DPA n=190 n=69 n=86 n=35
DPA1*01 178 93.7 64 92.8 82 95.4 32 91.4 P=0.49 P=0.81 P=0.40
DPA1*02 58 30.5 19 27.5 29 33.7 10 28.6 P=0.41 P=0.91 P=0.58
HLA-DPB n=185 n=65 n=85 n=35
DPB1*01 25 13.5 7 10.8 14 16.5 4 11.4 P=0.32 F=1.0 F=0.58
DPB1*02 56 30.3 16 24.6 29 34.1 11 31.4 P=0.21 P=0.46 P=0.78
DPB1*03 22 11.9 7 10.8 12 14.1 3 8.6 P=0.54 F=1.0 F=0.55
DPB1*04 142 76.8 53 81.5 61 71.8 28 80.0 P=0.16 P=0.85 P=0.35
HLA-DQA n=190 n=69 n=86 n=35
DQA1*01 136 71.6 49 71.0 58 67.4 29 82.9 P=0.63 P=0.19 P=0.087
DQA1*02 42 22.1 15 21.7 19 22.1 8 22.9 P=0.96 P=0.90 P=0.93
DQA1*03 58 30.5 22 31.9 28 32.6 8 22.9 P=0.93 P=0.34 P=0.29
DQA1*05 84 44.2 27 39.1 41 47.7 16 45.7 P=0.29 P=0.52 P=0.84
HLA-DQB n=190 n=69 n=86 n=35
DQB1*02 69 36.3 19 27.5 37 43.0 13 37.1 P=0.046/Pc=0.85 P=0.32 P=0.55
DQB1*03 110 57.9 45 65.2 47 54.7 18 51.4 P=0.18 P=0.17 P=0.75
DQB1*05 58 30.5 17 24.6 25 29.1 16 45.7 P=0.54 P=0.029/Pc=0.68 P=0.079
DQB1*06 93 49.0 34 49.3 40 46.5 19 54.3 P=0.73 P=0.63 P=0.44
HLA-DR n=195 n=65 n=90 n=40
DRB1 49 25.1 14 21.5 22 24.4 13 32.5 P=0.67 P=0.21 P=0.34
DRB51 61 31.3 24 36.9 23 25.6 14 35.0 P=0.13 P=0.84 P=0.27
DRB52 124 63.6 40 61.5 60 66.7 24 60.0 P=0.51 P=0.88 P=0.46
DRB53 91 46.7 32 49.2 41 45.6 18 45.0 P=0.65 P=0.67 P=0.95
*Phenotype frequencies .5% are listed.
!n represents the number of subjects with a specific allele phenotype. Alleles in bold showed an uncorrected P,0.05 followed by a corrected Pc (P/Pc).
doi:10.1371/journal.pone.0022948.t003
Figure 1. Combinations of ‘‘susceptible’’ (S) and ‘‘protective’’
(P) alleles. The histogram displays the percentage of subjects with the
phenotype indicated below the X axis in the three WNV
+ groups:
asymptomatic (AS), symptomatic (S), and having a neuroinvasive
disease (ND). ** P,0.01 and * P,0.05.
doi:10.1371/journal.pone.0022948.g001
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asymptomatic and symptomatic WNV
+ subjects from the BSRI
cohort were mostly from the western and southern U.S., whereas
the symptomatic and neuroinvasive disease WNV
+ subjects from
the McMaster cohort were from Canada (Alberta, Saskatchewan,
Manitoba, and Ontario). One could argue that the differences
observed within these two non-Hispanic mostly white cohorts
might be attributed to intrinsic differences between these
geographically distinct populations. To address this concern, we
compared the frequencies of allele phenotypes observed in the
WNV
+ symptomatic subjects from the BSRI cohort with those
observed in the McMaster cohort. No significant difference was
found in the distribution of the allele phenotypes of interest, which
confirmed that the differences observed between the WNV
infection outcome groups were not due to intrinsic differences
between the cohorts.
Absence of synergistic effect of age and allele phenotype
on disease outcome
Previous studies have shown that advanced age is associated
with poor outcome of WNV infection [9,35]. Consistent with this,
in the present study ND subjects from the McMaster cohort
exhibited a higher mean age (54.4 years old) than AS and S
subjects from the McMaster or BSRI cohorts (49.8, 48.7, and 48.4
years old, respectively; for ND vs. S McMaster P=0.037,
OR=0.97, and 95%CI 0.94–0.99) (Table 1). In a univariate
analysis using WNV infection outcome and continuous age
variables (data not shown), age was also strongly associated with
neuroinvasive disease outcome when S and ND subjects were
compared (PSv s .N D =0.02, OR=1.03, and 95%CI 1.01–1.06).
Furthermore, classifying the WNV
+ subjects in this study in five
age groups (18–34 used as the reference group, 35–44, 45–54, 55–
64, and .64), we confirmed that elderly people (.64) are more at
risk for the development of a neuroinvasive disease than younger
people (for S vs. ND, P(.64) vs. (18–34)=0.002, OR=2.92, and
95%CI 0.77–11.07).
In this study we report a potential association between HLA
alleles and disease outcome, and as age is a WNV disease outcome
risk factor, we evaluated whether there was an interaction between
HLA alleles and age. A logistic regression analysis restricted to
subjects bearing the A*68, C*08, DQB1*05, B*40, or C*03 alleles
was performed (Table 4). The magnitude of the association
between alleles and infection outcome was consistent with or
without age-adjustment for all alleles (A*68 age-adjusted PND vs.
AS=0.034, C*03 age-adjusted PND vs. AS=0.032, and B*40 age-
adjusted PAS vs. S=0.026) except for DQB1*05 (unadjusted PND vs
AS=0.031, age-adjusted PND vs. AS=0.095), showing that the
finding of DQB1*05 being associated with neuroinvasive disease
might be driven by age (Table 4). Furthermore, the odds ratios did
not change when age was included: ND subjects were 10 fold more
likely to have A*68 allele than AS subjects (PND vs. AS=0.034,
OR=10.3, and 95% CI 1.18–89.9), and ND had a 75% lower
chance of having B*40 or C*03 alleles than AS (for B*40, PND vs.
AS=0.068, OR=0.23, and 95% CI 0.04–1.12 and for C*03, PND
vs. AS=0.031, OR=0.23, and 95% CI 0.06–0.88). When age was
added as a predictive factor, there was no synergistic effect of age
and allele on disease outcome when comparing ND vs. AS groups.
Among symptomatic subjects, multivariable regression analysis
revealed that older individuals were more likely to have
neuroinvasive disease, independently of HLA allele phenotype
(effect of age among WNV
+ subjects, ND vs. S, PA*68=0.041,
PC*08=0.043, PDQB1*05=0.039, PB*40=0.031).
Comparison of HLA allele frequencies between WNV
infection outcome groups and the North American
population
Our study was limited by the number of WNV infected subjects
in our cohorts. One way to validate the results was to compare the
Table 4. Combined effect of age and allele phenotype on disease outcome using logistic regression analysis comparing
asymptomatic (AS), symptomatic (S), and neuroinvasive disease (ND) outcome groups.
ND vs. AS S vs. ND
Allele Logistic regression P-value OR 95% CI P-value OR 95% CI
Lower Upper Lower Upper
Age as predictor 0.21 1.02 0.99 1.05 0.041 1.03 1.00 1.06
A*68 Age adjustment 0.034 10.34 1.19 89.97 0.49 1.50 0.47 4.77
No adjustment 0.030 10.94 1.26 94.64 0.31 1.79 0.58 5.54
Age as predictor 0.17 1.02 0.99 1.05 0.031 1.03 1.00 1.06
B*40 Age adjustment 0.069 0.23 0.05 1.12 0.99 0.99 0.18 5.32
No adjustment 0.064 0.23 0.05 1.09 0.73 0.75 0.14 3.88
Age as predictor 0.14 1.02 0.99 1.06 0.11 1.03 0.99 1.06
C*03 Age adjustment 0.032 0.24 0.06 0.88 0.13 0.36 0.10 1.35
No adjustment 0.036 0.25 0.07 0.91 0.06 0.30 0.08 1.07
Age as predictor 0.17 1.02 0.99 1.06 0.043 1.04 1.00 1.07
C*08 Age adjustment N/A N/A N/A N/A 0.19 2.57 0.62 10.60
No adjustment N/A N/A N/A N/A 0.20 2.46 0.61 9.89
Age as predictor 0.27 1.02 0.99 1.05 0.039 1.03 1.00 1.07
DQB1*05 Age adjustment 0.095 2.18 0.87 5.43 0.17 1.81 0.78 4.19
No adjustment 0.031 2.58 1.09 6.10 0.08 2.06 0.91 4.63
doi:10.1371/journal.pone.0022948.t004
HLA Association with WNV Infection Outcome
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We compared the allele frequencies in each WNV infection
outcome group (AS, S, and ND) with those in the North American
European population, as reported on the NCI dbMHC website
[36] (Figure 2). Consistent with the findings from the comparison
of AS vs. ND groups, the frequencies of the ‘‘susceptible’’ alleles
HLA-A*68 and HLA-C*08 were lower in the AS WNV
+ subjects
and higher in the ND WNV
+ subjects than they were in the North
American European population (HLA-A*68 frequency in
AS=0.8%, NA=3.9%, ND=8.8%; and HLA-C*08 frequency
in AS=0%, NA=3.9%, ND=6.9%); however, these differences
did not reach statistical significance (for HLA-A*68 PAS vs.
NA=0.101 and PND vs. NA=0.074, and for HLA-C*08 PND vs.
NA=0.29).
In contrast, but as expected, the frequencies of the ‘‘protective’’
alleles HLA-B*40 and HLA-C*03 were higher in the asymptom-
atic WNV
+ subjects and lower in the group of WNV
+ subjects with
neuroinvasive disease than in the North American European
population (for HLA-B*40, AS=10.6%, NA=8.4%, S=3.4%,
ND=2.7% and for HLA-C*03, AS=18.2%, NA=15.4%,
S=14.7%, ND=5.2%); differences in two of the comparison
groups reached statistical significance (for HLA-B*40 PS vs.
NA=0.029 and for HLA-C*03 PND vs. NA=0.032).
Distribution of HLA-A*68, B*40, C*03, and C*08 alleles
across various world populations
The allele frequencies in various world populations are reported
on the NCI dbMHC website [36], and they were used to compare
the ‘‘susceptible’’ and ‘‘protective’’ allele frequencies between
European and other world populations from Africa, New World,
Asia, and Australia (Figure 3). Interestingly, European, African,
and New World populations have the highest frequencies of the
‘‘susceptible’’ alleles A*68 and C*08. For A*68 allele frequency,
Australian,Asia,European,New World,African (all P,0.0001
when compared with European) and for C*08 allele frequency
Australian,Asia,New World,African,European (all P,0.0001
when compared with European). Additionally, European and
African population have the lowest frequencies of the ‘‘protective’’
allele B*40 and intermediate to low frequencies of C*03. For B*40
allele frequency, African,European,Asian,New World,Aus-
tralian (all P,0.0001 when compared with European) and for
C*03 allele frequency Australian,African,European,Asian,
New World (all P,0.0001 when compared with European, except
Australian vs. European P,0.05). According to this observation,
European and African populations might be more at risk for the
development of neurological disease after WNV infection.
Discussion
This comparison of allele distributions across groups of WNV
+
subjects with different infection outcomes revealed higher
frequencies of the alleles HLA-A*68, HLA-C*08, and HLA-
DQB1*05 in subjects experiencing neuroinvasive disease than in
asymptomatic subjects, and these alleles were present at
intermediate frequencies in symptomatic subjects. These alleles
were designated ‘‘susceptible’’ because they were more frequently
found in the group experiencing neuroinvasive disease. Converse-
ly, the alleles HLA-B*40 and HLA-C*03 were present at higher
frequencies in the group of asymptomatic WNV
+ subjects than in
the group of WNV
+ subjects with neuroinvasive disease; they were
present at intermediate frequencies in the group of symptomatic
subjects. These alleles were designated ‘‘protective’’ because they
were more frequently found in the group of asymptomatic WNV
+
subjects. After correction for the effect of advanced age on disease
severity [9], all of the above associations with infection outcome
remained, with the exception of the finding of DQB1*05 being
associated with neurological disease. Overall, the presence of
‘‘protective’’ or ‘‘susceptible’’ alleles was associated with whether
WNV
+ subjects would develop symptoms or remain asymptom-
atic, and age was associated with the development of neuroinva-
sive disease in the subset of subjects with symptomatic WNV
infection.
Figure 2. ‘‘Susceptible’’ and ‘‘protective’’ alleles in the North American population and in the WNV
+ cohort. The histogram displays the
allele frequency of each ‘‘susceptible’’ and ‘‘protective’’ allele in the North American population and in the asymptomatic (AS), symptomatic (S), and
having neuroinvasive disease (ND) WNV
+ individuals. * P,0.05.
doi:10.1371/journal.pone.0022948.g002
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samples from WNV
+ subjects with the full spectrum of WNV
infection outcomes. The combination of two cohorts of WNV
+
subjects allowed comparison of samples from asymptomatic and
symptomatic blood donors, as well as with samples from
symptomatic and neuroinvasive disease patients enrolled through
hospitals and doctors’ offices. The comparison between extreme
infection outcomes (AS vs. ND) revealed statistically significant
differences that would have been missed if the allele phenotypes of
WNV
+ subjects had only been compared within each of the two
cohorts. However, the sample size of our cohorts in this study is
relatively small, limiting the power to detect associations between
HLA alleles and infection outcome. In a total of 210 WNV
+
subjects divided into three groups according to their infection
outcomes, as many as 53 alleles were found in more than 5% of
the study population. Consequently, the P values after correction
for multiple comparisons were higher than 0.05 and only one
corrected P value was lower than 0.1 (C*08 PcAS vs. ND=0.064).
To help substantiate our findings, a second confirmatory analysis
was performed using an external control group, a North American
European population with reported allele frequencies [36]. Higher
frequencies of ‘‘susceptible’’ alleles and lower frequencies of the
‘‘protective’’ alleles were found in the ND group than in the North
American European control population, and the converse was
found comparing the AS group to the control population with
alleles B*40 and C*03 confirmed as ‘‘protective’’ alleles using this
confirmatory analysis. However, the HLA allele associations in this
study have not been tested in a second WNV
+ population, which
would be ideal to confirm the validity of the results.
It was of interest to compare the distribution of ‘‘protective’’ and
‘‘susceptible’’ HLA alleles in the world population. European and
African populations seem to have higher frequencies of the
‘‘susceptible’’ alleles A*68 and C*08 and lower frequencies of the
‘‘protective’’ alleles B*40 and C*03 (Figure 3) [36]. Even though
different clades of lineage 1 of WNV are circulating around the
world, most WNV outbreaks with reported neuroinvasive disease
occurred in Africa [37,38,39], Europe [40,41,42,43], Israel [44],
and North America [45] (where more than 70% are white and
more than 10% are black) [46]. The association between these two
observations is highly speculative (as neurological diseases might
have been under-recognized and under-reported in other areas of
the world), but nevertheless interesting; further studies in each of
those populations are required to confirm this potential associa-
tion.
From an immunological perspective, the differences between
AS and ND groups that remained significant after adjustment for
subject age are related to HLA class I alleles. Considering the
importance of the CD8
+ T cell response in viral clearance
[47,48,49], a comparison of the levels of WNV-specific T cell
responses would be of great interest. Further studies are required
to evaluate the differences in WNV antigen presentation capacity
of each of these HLA class I molecules.
HLA class I and class II alleles have been associated with other
neurological disorders. Multiple sclerosis, an auto-immune disease
that has been controversially reported as being possibly triggered
by viral infections [50], is positively associated with HLA-A*02,
C*08, DRB1*15, DQA1*01, and DQB1*06 [51,52], whereas
HLA-B*44 is reported to be protective [53]. The HSV-induced
Behcet’s syndrome [54] is more common in individuals expressing
HLA-B*51 [55,56]. Guillain-Barre ´ syndrome is of unknown
etiology but has been reported after viral infections including
WNV [57,58]; and the syndrome is associated with HLA-B*44,
Cw*01 [59], DRB1*0803 [60] and DRB1*13 [61]. For the related
flavivirus and dengue infection, a protective role was reported in a
Thai population for alleles A*0203, B*13, B*44, B*52, B*62,
B*76, B*77, A*29 in Cubans, A*33 in Vietnamese, B*14 in
Cubans and for HLA Class II DRB1*04 in Mexicans [62].
Susceptibility to dengue hemorrhagic fever was correlated with
HLA-A*1 in Cubans, A*2, A*0207, B*46, and B*51 in Thai, A*24
in Vietnamese, and HLA-DQ1 and DR1 in Brazilians [62]. Of the
various alleles reported as associated with neurological diseases or
flavivirus infection, only HLA-C*08 allele was also found to be
associated with symptomatic WNV infection in our study.
To our knowledge, this is the first study of the association
between HLA alleles and WNV infection outcome, providing,
upon confirmation, valuable information for the design of future
WNV vaccines and for understanding WNV pathogenesis. Further
studies will be required to confirm that HLA-A*68 and C*08 are
Figure 3. ‘‘Susceptible’’ and ‘‘protective’’ allele frequencies in world populations. The histogram displays the allele frequency of each
‘‘susceptible’’ and ‘‘protective’’ allele in various world populations. The North and sub-Saharan Africa were regrouped under Africa, North and South
America were regrouped under New World, and Oceania, northwest, southeast, and southwest Asia were regrouped under Asia, Australia represents
aboriginal populations only. *** P,0.0001 and * P,0.05 for Europe vs. comparison population.
doi:10.1371/journal.pone.0022948.g003
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alleles and to explore the mechanism of how these alleles might
interact with WNV-specific epitopes. From a public health
perspective, the results of this study confirm that older individuals
with at risk genetic background could have priority access to the
latest prophylactic and therapeutic solutions in case of a large
outbreak of WNV.
Methods
Study subjects
A total of 210 WNV
+ subjects (206 white, 2 Asian, 1 Native
American, and 1 black, all non-Hispanic) from two different
cohorts were enrolled in this study (Table 1). The first cohort
consisted of 102 asymptomatic and mildly symptomatic WNV
+
blood donors enrolled through the Blood Systems Research
Institute (BSRI), and the second cohort included 108 WNV
+
patients with moderate to severe symptoms enrolled by researchers
at McMaster University (Table 1).
BSRI enrolled 102 blood donors from the United Blood
Services blood centers who tested positive for WNV RNA by
routine donation screening. Infection was confirmed using follow-
up samples showing seroconversion to anti-WNV IgM. Samples
were collected at regional blood centers and were shipped by
overnight courier to BSRI. Symptom questionnaires covering 12
possible WNV-related symptoms (fever, headache, eye pain, body
aches, new skin rash, swollen lymph nodes, nausea or vomiting,
muscle weakness, confusion, disorientation, memory problems, or
other symptom) were administered at study enrollment and two
weeks later. Based on previous studies in which WNV false positive
donors reported up to 3 symptoms [7,63], a cutoff of four
symptoms was used to classify blood donors as asymptomatic (AS,
number of reported symptoms,4, n=69) or symptomatic (S,
number of reported symptoms consistent with West Nile fever $4,
n=33).
McMaster University enrolled 103 symptomatic WNV
+ pa-
tients. These WNV
+ patients were enrolled through doctors’
offices and hospitals. The WNV
+ patients who experienced
symptoms consistent with West Nile fever but who did not meet
the criteria for neuroinvasive disease were classified as symptom-
atic (S, n=62), and those who experienced neuroinvasive disease
were grouped as having neuroinvasive disease (ND, n=46, with
37.1% reporting encephalitis, 4.3% meningitis, 8.6% meningoen-
cephalitis, and 50% acute flaccid paralysis).
Ethics statement
All of BSRI donors were enrolled after obtaining written
informed consent. The research protocol was approved by the
UCSF Committee on Human Research.
McMaster University enrolled 103 symptomatic WNV
+ patients
after written consent form was obtained. The research protocol
was approved by the Research Ethics Board of McMaster
University.
HLA genotyping of the BSRI cohort
Genomic DNA was prepared from peripheral blood mononu-
clear cells (PBMCs) of WNV
+ subjects using a QIAamp DNeasy
Blood and Tissue Kit (QIAGEN, Valencia, CA) according to the
manufacturer’s protocol.
PCR amplification. Using patients’ genomic DNA at a
concentration of 40 ng/ml, exons 2 and 3 and intron 2 were
amplified for HLA-A, B and C, whereas exon 2 was amplified for
HLA-DPA1, DPB1, DQA1, DQB1, and DRB using gene-specific
primers. Additional PCR and sequencing reactions were performed
for HLA-DRB using a two-step sequence-based genotyping method
described by Luo et al. [64].
The 50-ml PCR reaction mixtures consisted of 60 mM Tris-HCl
(pH 9.0), 15 mM (NH4)2SO4, 1.5 mM MgCl2, 0.1% gelatin,
100 mM each type of dNTPs, 25 pmol each primer, 1.25 Units of
Taq DNA polymerase (Invitrogen Life Technologies, Burlington,
ON, Canada) and 200 ng of DNA.
Amplification of PCR products of the correct size was
confirmed by gel electrophoresis using a 1% gel with ethidium
bromide. PCR products were purified using a Millipore Multi-
screen HTSTM plate (Millipore Corporation, Bedford, MA) and
were re-suspended in double distilled water.
Sequencing PCR. The purified PCR products were
sequenced for exons 2 and 3 (codons 2 to 90 and 92 to 182,
respectively) for class I loci and exon 2 for class II loci using a
BigDyeTM Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA). Allele-specific primers were used to resolve ambiguous allele
combinations.
Sequencing and HLA typing. ABI PRISM BigDye
Terminator Cycle Sequencing Ready Reaction Kits (Applied
Biosystems, Foster City, CA, USA) were used for sequencing. The
amplified PCR products were purified and analyzed using an ABI
PRISM 310 GENETIC ANALYZER (Applied Biosystems). Class I
and II genotyping was analyzed using a program developed based
on Taxonomic Based Sequencing Analysis (TBSA) [65] and Codon
Express
TM, which is a computer program designed to analyze
sequence output for genotyping. The HLA databases were
downloaded from the IMTG/HLA Database (http://www.ebi.ac.
uk/imgt/hla/).
HLA genotyping of the McMaster cohort
High-resolution HLA typing was performed by Sequence Based
Typing (SBT) at the University of Oklahoma Health Science
Center CLIA/ASHI-accredited HLA typing laboratory using in-
house methods. Briefly, genomic DNA was extracted from PBMCs
using a QIAamp DNA blood kit (QIAGEN). After confirmation,
the PCR product was purified using an ExoSAP-IT kit (USB) and
was sequenced using BigDyeH Terminator v3.1 (APPLIED
BIOSYSTEMS) chemistry. Dye removal was conducted by
ethanol precipitation. Sequencing reactions were performed on a
3730 Capillary Electrophoresis DNA Sequencer (APPLIED
BIOSYSTEMS). Four-digit HLA types were determined using
the HLA typing program Assign SBT (Conexio Genomics).
Statistical analysis
To examine the association of each HLA allele (HLA-A, B, C,
DP, DQ, and DR) with WNV infection outcome, we examined
the frequency of each allele in each group of WNV
+ subjects, i.e.
AS, S, and ND. Allele frequencies were calculated using a direct
counting method. The frequency distributions of each allele in the
AS, S, and ND groups or in the North American European
population were compared pair-wise using the x
2 test; a Fisher’s
exact two-tailed test was used where appropriate using the FREQ
procedure (SAS/STAT 9.1.3), and the odds ratios (ORs) and 95%
confidence intervals (CIs) for individuals with a specific allele
phenotype or allele frequency were calculated using the Woolf
method [66]. P,0.05 was considered statistically significant.
Corrected P values (Pc) were obtained from SAS using the
bootstrap method, which provided the false discovery rate after
correction for multiple comparisons of 53 alleles. The PROC
LOGISTIC (SAS/STAT 9.1.3), logistic regression analysis was
used (SAS 9.1) in order to determine the effect of age on severity of
WNV infection outcome variable. First, age was included in the
model as a continuous predictor. Then five age categories were
HLA Association with WNV Infection Outcome
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18–34 was used as a reference group. Three infection outcome
variables were used (AS, S, and ND) and combinations of levels AS
vs. S, AS vs. ND, and S vs. ND were used as separate models. The
PROC LOGISTIC (SAS/STAT 9.1.3), multivariate logistic
regression, was used to calculate regression coefficients for each
group of WNV infection outcomes. WNV outcome and HLA
allele covariates were treated as binary variables and age was
treated as a continuous variable.
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